Yang H, Rosove M H, Figlin R A
The Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles 90095, USA.
Am J Hematol. 1999 Dec;62(4):247-50. doi: 10.1002/(sici)1096-8652(199912)62:4<247::aid-ajh9>3.0.co;2-t.
Rituximab, an anti-CD20 antibody, has been recently approved for the treatment of low-grade or follicular non-Hodgkin's lymphoma (NHL). Because of its relatively benign side effect profile, it has been considered a nontoxic alternative to chemotherapy. Recently, however, tumor lysis syndrome (TLS) resulting from rituximab has been reported in a patient with chronic lymphocytic leukemia (CLL). We herein present two cases of rituximab-induced TLS. The first case occurred in a patient with high-grade NHL, while the second case occurred in a patient with CLL. We also present a summary of the literature regarding TLS induced by immunotherapies.
利妥昔单抗是一种抗CD20抗体，最近已被批准用于治疗低度或滤泡性非霍奇金淋巴瘤（NHL）。由于其相对温和的副作用，它被认为是化疗的无毒替代方案。然而，最近有报道称一名慢性淋巴细胞白血病（CLL）患者因利妥昔单抗出现肿瘤溶解综合征（TLS）。我们在此报告两例利妥昔单抗诱导的TLS病例。第一例发生在一名高度恶性NHL患者中，第二例发生在一名CLL患者中。我们还总结了关于免疫疗法诱导TLS的文献。
